These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 32562878)

  • 1. Clinical and Economic Outcomes in Patients with Persistent Asthma Who Attain Healthcare Effectiveness and Data Information Set Measures.
    Mosnaim G; Huang H; Ariely R; DePietro M; Jiang M; Ramakrishnan K; Batista AE; Lang K; Near AM
    J Allergy Clin Immunol Pract; 2020; 8(10):3443-3454.e2. PubMed ID: 32562878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Outcomes, Health Care Resource Use, and Costs Associated with High Versus Low HEDIS Asthma Medication Ratio.
    Luskin AT; Antonova EN; Broder MS; Chang E; Raimundo K; Solari PG
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1117-1124. PubMed ID: 29083971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HEDIS Medication Management for People with Asthma Measure is Not Related to Improved Asthma Outcomes.
    Crans Yoon A; Crawford W; Sheikh J; Nakahiro R; Gong A; Schatz M
    J Allergy Clin Immunol Pract; 2015; 3(4):547-52. PubMed ID: 25758917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and outcomes associated with two asthma quality of care measures.
    Blackburn J; Sharma P; Liu Y; Morrisey MA; Menachemi N; Sen B; Sanders T; Becker DJ
    J Asthma; 2022 Nov; 59(11):2283-2291. PubMed ID: 34669533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of asthma control to asthma exacerbations using surrogate markers within a managed care database.
    Schatz M; Zeiger RS; Yang SJ; Chen W; Crawford WW; Sajjan SG; Allen-Ramey F
    Am J Manag Care; 2010 May; 16(5):327-33. PubMed ID: 20469953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of administrative claims-based risk predictors for pediatric asthma.
    Andrews AL; Brinton DL; Simpson AN
    Am J Manag Care; 2021 Dec; 27(12):533-537. PubMed ID: 34889577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA.
    Suruki RY; Daugherty JB; Boudiaf N; Albers FC
    BMC Pulm Med; 2017 Apr; 17(1):74. PubMed ID: 28449686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes.
    Berger WE; Legorreta AP; Blaiss MS; Schneider EC; Luskin AT; Stempel DA; Suissa S; Goodman DC; Stoloff SW; Chapman JA; Sullivan SD; Vollmer B; Weiss KB
    Ann Allergy Asthma Immunol; 2004 Dec; 93(6):538-45. PubMed ID: 15609762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How well do the HEDIS asthma inclusion criteria identify persistent asthma?
    Mosen DM; Macy E; Schatz M; Mendoza G; Stibolt TB; McGaw J; Goldstein J; Bellows J
    Am J Manag Care; 2005 Oct; 11(10):650-4. PubMed ID: 16232006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma Quality Measurement and Adverse Outcomes in Medicaid-Enrolled Children.
    Jefferson AA; Brown CC; Eyimina A; Goudie A; Rezaeiahari M; Perry TT; Tilford JM
    Pediatrics; 2023 Aug; 152(2):. PubMed ID: 37497577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
    Lage MJ; Gross GN; Brewster C; Spalitto A
    Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity of the HEDIS criteria to identify children with persistent asthma and sustained high utilization.
    Fuhlbrigge AL; Carey VJ; Finkelstein JA; Lozano P; Inui TS; Weiss ST; Weiss KB
    Am J Manag Care; 2005 May; 11(5):325-30. PubMed ID: 15898221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does diabetes disease management save money and improve outcomes? A report of simultaneous short-term savings and quality improvement associated with a health maintenance organization-sponsored disease management program among patients fulfilling health employer data and information set criteria.
    Sidorov J; Shull R; Tomcavage J; Girolami S; Lawton N; Harris R
    Diabetes Care; 2002 Apr; 25(4):684-9. PubMed ID: 11919125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flunking asthma? When HEDIS takes the ACT.
    Lim KG; Patel AM; Naessens JM; Li JT; Volcheck GW; Wagie AE; Enders FB; Beebe TJ
    Am J Manag Care; 2008 Aug; 14(8):487-94. PubMed ID: 18690764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between common asthma therapies and recurrent asthma exacerbations in children enrolled in a state Medicaid plan.
    Camargo CA; Ramachandran S; Ryskina KL; Lewis BE; Legorreta AP
    Am J Health Syst Pharm; 2007 May; 64(10):1054-61. PubMed ID: 17494905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of asthma prescription measures and health system performance based on emergency department utilization.
    Fuhlbrigge A; Carey VJ; Adams RJ; Finkelstein JA; Lozano P; Weiss ST; Weiss KB
    Med Care; 2004 May; 42(5):465-71. PubMed ID: 15083107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
    Friedman HS; Yawn BP
    Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Process quality measures and asthma exacerbations in the medicaid population.
    Yong PL; Werner RM
    J Allergy Clin Immunol; 2009 Nov; 124(5):961-6. PubMed ID: 19748660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Care Utilization and Direct Costs in Mild, Moderate, and Severe Adult Asthma: A Descriptive Study Using the 2014 South Korean Health Insurance Database.
    Lee YJ; Kwon SH; Hong SH; Nam JH; Song HJ; Lee JS; Lee EK; Shin JY
    Clin Ther; 2017 Mar; 39(3):527-536. PubMed ID: 28196623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
    Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.